A unit dosage of an oral composition of an extract of Withania somnifera is disclosed. The extract of Withania somnifera includes total withanolides. The total withanolides includes withanolide glycosides and withanolide aglycones. The extract of Withania somnifera includes about 32% to about 38% by weight of the withanolide glycosides. Methods of preparing the extract of Withania somnifera are disclosed. Methods of treatment by administering the extract of Withania somnifera are disclosed.

The present invention relates to a new formulation of specific nutritional ingredients (nutraceuticals) and/or pharmaceutical compounds.

The present invention relates to a new delivery system for nutritional ingredients (nutraceuticals). These nutritional ingredients are useful for gut and metabolic health in monogastric animals, especially in humans.

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.

An article of manufacture is described comprising the combination of an adjunct material and a delivery particle. The delivery particle comprising a benefit agent core material and a shell encapsulating the core material is described, along with a process for forming such a delivery particle and articles of manufacture. The shell is the reaction product of: i) an isocyanate or acid chloride or acrylate with ii) an amine-containing natural material having free amino moieties, and iii) an α, β-unsaturated compound, the α, β-unsaturated compound forming C—N covalent bonds with the amine moieties of the natural material. The delivery particle of the invention has improved release characteristics, with enhanced degradation characteristics in OECD test method 301B.

A method for using treated biochar to reduce the overall environmental impact of farming and minimize the carbon footprint of farms is provided. The method comprising engaging in one or more of the following practices: (1) combining treated biochar with feed or using biochar as feed for animals to reduce methane from enteric fermentation and increase animal health and nutrition; (2) combining treated biochar with compost, animal bedding or manure piles to reduce odor and increase nutrient retention; (3) applying treated biochar to lagoons to reduce odor and treat water; (4) applying treated biochar to pastures to increase pasture health; (5) applying treated biochar to crops to increase crop productivity, healthier roots and prevent fertilizer leaching; and (6) using the carbon negativity of a produced biochar to reduce the overall farm or ranch carbon footprint.

Provided is a microcapsule for increasing the survival and/or function of a cell, such as an islet cell, microcapsule can include an outer shell comprising a first polymer; an interior core comprising: at least one live cell; a second polymer; and at least one microsphere comprising a third polymer and a compound capable of improving survival of the at least one cell. The improved survival and/or function of the at least one live cell in the microcapsule is compared to a live cell in a microcapsule in the absence of the compound capable of improving survival of the at least one cell. The first and second polymer may include alginate and the third polymer (used for the microsphere) may comprise PLGA. The compound may include a GLP-1 receptor agonist. Also provided are methods for producing such microcapsules; insulin delivery systems using the microcapsules, and methods to treat disease, such as diabetes, using the microcapsules.

Described herein are RPE cells engineered to secrete a FVII protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating a patient with hemophilia or FVII deficiency.

The present disclosure provides methods and systems for forming stable droplets as part of an emulsion. The emulsion may be, for example, formed by bringing an aqueous phase in contact with an oil phase at a droplet generation junction of a droplet generator. Droplets of the present disclosure may be used for holding compositions for various uses.

The present invention relates to an active substance delivery system, preferably an anti-cancer agent delivery system, for use in the treatment of cancer in a human subject, comprising one or more anti-cancer agents and optionally further active substances, both included in nano- and/or microparticles, and a method for producing such a delivery system.